Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 8555026)

1.

Prognostic value of Ki67 antigen expression in basal cell carcinomas.

Healy E, Angus B, Lawrence CM, Rees JL.

Br J Dermatol. 1995 Nov;133(5):737-41.

PMID:
8555026
3.

Prognostic value of Ki-67, CD31 and epidermal growth factor receptor expression in basal cell carcinoma.

Yerebakan O, Ciftçioglu MA, Akkaya BK, Yilmaz E.

J Dermatol. 2003 Jan;30(1):33-41.

PMID:
12598707
4.

Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity.

Sittel C, Ruiz S, Volling P, Kvasnicka HM, Jungehülsing M, Eckel HE.

Oral Oncol. 1999 Nov;35(6):583-9.

PMID:
10705094
6.

Immunology and growth characteristics of ocular basal cell carcinoma.

Rohrbach JM, Stiemer R, Mayer A, Riedinger C, Duijvestijn A, Zierhut M.

Graefes Arch Clin Exp Ophthalmol. 2001 Jan;239(1):35-40.

PMID:
11271459
7.

Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53.

Abdelsayed RA, Guijarro-Rojas M, Ibrahim NA, Sangueza OP.

J Cutan Pathol. 2000 Apr;27(4):169-75.

PMID:
10774937
8.

Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis.

Vidal D, Matías-Guiu X, Alomar A.

Br J Dermatol. 2004 Sep;151(3):656-62.

PMID:
15377354
9.
10.

Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma.

Sittel C, Eckel HE, Damm M, von Pritzbuer E, Kvasnicka HM.

Laryngoscope. 2000 Jun;110(6):1012-7.

PMID:
10852523
11.

Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma.

Barrett TL, Smith KJ, Hodge JJ, Butler R, Hall FW, Skelton HG.

J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):430-7.

PMID:
9308559
12.

[Survival of patients with laryngeal cancer and some prognostic factors].

Gryczyński M, Kobos J, Murlewska A, Pietruszewska W.

Otolaryngol Pol. 2003;57(3):329-40. Polish.

PMID:
14524174
13.

Perianal Bowen's disease: a clinicopathologic study of 47 patients.

Marchesa P, Fazio VW, Oliart S, Goldblum JR, Lavery IC.

Dis Colon Rectum. 1997 Nov;40(11):1286-93.

PMID:
9369101
14.

Immunophenotypic analysis of the p53 gene in non-melanoma skin cancer and correlation with apoptosis and cell proliferation.

Stratigos AJ, Kapranos N, Petrakou E, Anastasiadou A, Pagouni A, Christofidou E, Petridis A, Papadopoulos O, Kokka E, Antoniou C, Georgala S, Katsambas AD.

J Eur Acad Dermatol Venereol. 2005 Mar;19(2):180-6.

PMID:
15752287
15.

Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.

Zagrodnik B, Kempf W, Seifert B, Müller B, Burg G, Urosevic M, Dummer R.

Cancer. 2003 Dec 15;98(12):2708-14.

16.

Growth fractions in bladder cancer defined by Ki67: association with cancer grade, category and recurrence rate of superficial lesions.

Stavropoulos NE, Ioackim-Velogianni E, Hastazeris K, Kitsiou E, Stefanaki S, Agnantis N.

Br J Urol. 1993 Nov;72(5 Pt 2):736-9.

PMID:
8281405
17.

[Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67].

Rodríguez Alonso A, Pita Fernández S, González-Carreró J, Nogueira March JL.

Actas Urol Esp. 2003 Feb;27(2):132-41. Review. Spanish.

PMID:
12731328
18.

Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.

Vidal D, Matías-Guiu X, Alomar A.

Clin Exp Dermatol. 2004 Sep;29(5):518-25.

PMID:
15347339
19.

[Evaluation of Ki67 antigen using MIB1 antibody as a prognostic factor in renal pelvic and ureteral cancer].

Kojima K, Naruo S, Kanayama H, Kagawa S.

Nihon Hinyokika Gakkai Zasshi. 1996 May;87(5):822-30. Japanese.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk